Foundation Medicine (FMI) Tops Q4 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Leerink Partners Reiterates Market perform After Foundation Medicine (FMI) Reports Weak 2016 Guidance
February 24, 2016 9:35 AM ESTLeerink Partners reiterated a Market Perform rating on Foundation Medicine (NASDAQ: FMI), and cut the price target to $15.00 (from $27.00), following the company's 4Q earnings report. FMI reported 4Q revenue of $26.1M, above the Street's $25.1M estimate. 2016 revenue guidance of $110M-$120M was ~10%/6% below consensus at... More
